Literature DB >> 3782433

Increased renal sensitivity to vasopressin in two patients with essential hypernatremia.

D B Dunger, J R Seckl, S L Lightman.   

Abstract

Patients with essential hypernatremia maintain urinary concentrating ability despite plasma hyperosmolality and low plasma vasopressin concentrations. We investigated renal sensitivity to ultralow dose vasopressin infusions in two patients with a syndrome of hypodipsia, hypernatremia with selective osmoreceptor dysfunction, early puberty, and aggressive behavior. The patients were water loaded until a hypotonic diuresis was established. Vasopressin was infused in stepwise increments from 0.4-12 fmol/kg X min. Both patients had increased renal sensitivity to vasopressin, achieving negative free water clearance at infusion rates of 0.4 and 4 fmol/kg X min (normal greater than or equal to 6). Treatment for 3 months with 1-desamino-8-D-arginine vasopressin (DDAVP) led to an improvement in behavior and the reporting, for the first time, of a sensation of thirst. After DDAVP therapy both patients had a reduction of their renal sensitivity to infused vasopressin. We conclude that untreated patients with essential hypernatremia have increased renal sensitivity to vasopressin which is reduced by DDAVP administration.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3782433     DOI: 10.1210/jcem-64-1-185

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  3 in total

1.  [Severe hypernatremia in acquired disorder of thirst and vasopressin regulation].

Authors:  J Hensen; V Bähr; W Oelkers
Journal:  Klin Wochenschr       Date:  1988-06-01

Review 2.  Diabetes insipidus. Current treatment recommendations.

Authors:  J R Seckl; D B Dunger
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

3.  Hyponatremia associated with laryngeal squamous cell carcinoma.

Authors:  Y Roth; S L Lightman; J Kronenberg
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.